25P Platinum-based chemotherapy (PCT) addition to first-line PD-1/PD-L1 inhibitors (ICI) prevent hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) patients (pts) by reducing circulating immature neutrophils
| Autor: | Ferrara, R., Lo Russo, G., Ciniselli, C.M., Bassani, B., Calareso, G., Duroni, V., Di Gregorio, S., Proto, C., Prelaj, A., De Toma, A., Occhipinti, M., Brambilla, M., Manglaviti, S., Mazzeo, L., Ganzinelli, M., De Braud, F.G.M., Garassino, M.C., Colombo, M.P., Verderio, P., Sangaletti, S. |
|---|---|
| Zdroj: | In Immuno-Oncology and Technology December 2022 16 Supplement 1 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|